iShares Biotechnology ETF
902 hedge funds and large institutions have $5.71B invested in iShares Biotechnology ETF in 2022 Q4 according to their latest regulatory filings, with 141 funds opening new positions, 257 increasing their positions, 289 reducing their positions, and 45 closing their positions.
213% more first-time investments, than exits
New positions opened: 141 | Existing positions closed: 45
57% more funds holding in top 10
Funds holding in top 10: 14 → 22 (+8)
25% more capital invested
Capital invested by funds: $4.58B → $5.71B (+$1.13B)
9% more funds holding
Funds holding: 829 → 902 (+73)
3.65% more ownership
Funds ownership: 61.65% → 65.3% (+3.6%)
11% less repeat investments, than reductions
Existing positions increased: 257 | Existing positions reduced: 289
38% less call options, than puts
Call options by funds: $326M | Put options by funds: $525M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CANY
Caxton Associates (New York)
New York
|
+$149M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$137M |
| 3 |
E
Ergoteles
New York
|
+$85.8M |
| 4 |
Goldman Sachs
New York
|
+$72.3M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$51.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$77.3M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$58.8M |
| 3 |
Barclays
London,
United Kingdom
|
-$50.3M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$49.4M |
| 5 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
-$20.8M |
IBB Hedge Fund Activity: Q4 2022 in Review
902 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2022, worth a combined $5.71B — up 25% from $4.58B a quarter earlier.
Buyers outnumbered sellers: 141 funds opened new IBB positions and 45 closed out — a net gain of 96 holders — while 257 added to existing stakes and 289 trimmed.
The largest buyer was Caxton Associates (New York), opening a new position worth an estimated $149M. The largest seller was Morgan Stanley, cutting an estimated $77.3M.
- 902 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2022, up from 829 in Q3 2022.
- Funds reported $5.71B of iShares Biotechnology ETF stock for Q4 2022, up 25% quarter-over-quarter.
- 141 funds opened new iShares Biotechnology ETF positions in Q4 2022 and 45 closed out, a net change of +96 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2022 was Caxton Associates (New York), an estimated $149M added.
- The largest iShares Biotechnology ETF seller in Q4 2022 was Morgan Stanley, an estimated $77.3M sold.
Based on aggregated 13F filings for Q4 2022.